Vaccination strategies for minimizing loss of life in Covid-19 in a Europe lacking vaccines

  title={Vaccination strategies for minimizing loss of life in Covid-19 in a Europe lacking vaccines},
  author={Patrick R. Hunziker},
  • P. Hunziker
  • Published in medRxiv 1 February 2021
  • Medicine
Background: We aimed at identifying vaccination strategies that minimize loss of life in the Covid-19 pandemic. Covid-19 mainly kills the elderly, but the pandemic is driven by social contacts that are more frequent in the young. Vaccines elicit stronger immune responses per dose in younger persons. As vaccine production is a bottleneck, many countries have adopted a strategy of first vaccinating the elderly and vulnerable, while postponing vaccination of the young. Methods: Based on published… 
2 Citations
Minimizing loss of life in Covid-19 in a 100 day period in the U.S.A. by age-tailored dosing and distribution of a limited vaccine supply
Rapid reduction of Covid-19 case and death rate in the U.S. can be best achieved by using highly effective vaccines in an age-tailored dosing regimen, while an 'elderly first' approach costs more lives, even in the elderly.
Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence
It is shown that when the epidemic is exponentially growing the success of the booster campaign is highly sensitive to the timing of its initiation, and a rapid response is an important factor in reducing disease burden using booster vaccination.


Vaccine optimization for COVID-19: who to vaccinate first?
An age-stratified mathematical model determined optimal vaccine allocation for four different metrics (deaths, symptomatic infections, and maximum non-ICU and ICU hospitalizations) under a wide variety of assumptions and found that a vaccine with effectiveness would be enough to substantially mitigate the ongoing pandemic.
Age-targeted dose allocation can halve COVID-19 vaccine requirements
An age-structured mathematical model is used to investigate the benefits of optimizing age-specific dose allocation to suppress the transmission, morbidity and mortality of SARS-CoV-2 and the associated disease, COVID-19 and shows that optimizing the allocation of vaccine doses can more than double their effectiveness.
Looking beyond COVID-19 vaccine phase 3 trials.
After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps
Determinants of SARS-CoV-2 transmission to guide vaccination strategy in a city
It is shown that transmissions on the city population level are driven by the socioeconomically weaker and highly mobile groups, and vaccination of a third of the population at 90% efficacy prioritising the latter groups would induce a stronger preventive effect compared to vaccinating exclusively senior population groups first.
Estimating real-world COVID-19 vaccine effectiveness in Israel
Using counts of positive and hospitalized cases of vaccinated individuals, sensitive estimations of the vaccine effectiveness are provided by correcting to daily case incidence, finding high effectiveness of 66-85% in reducing SARS-CoV-2 positive cases and over 90%" in reducing severe hospitalizations.
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
The phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein in healthy adults found it induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100- μg dose in a phase 3 vaccine trial.
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
Current knowledge for existence of COVID-19 correlates of protection, methods for assessment of immune correlate of protection and issues related to CO VID-19 correlated of protection are reviewed.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
The mRNA-1273 vaccine induced anti-SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified, which support further development of this vaccine.
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease, and Aside from transient local and systemic reactions, no safety concerns were identified.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.